Abstract
Diabetes and associated comorbidities are a global health threat on the rise. We conducted a six-month dietary intervention in pre-diabetic individuals (NCT03222791), to mitigate the hyperglycemia and enhance metabolic health. The current work explores early diabetes markers in the 200 individuals who completed the trial. We find 166 of 2,803 measured features, including oral and gut microbial species and pathways, serum metabolites and cytokines, show significant change in response to a personalized postprandial glucose-targeting diet or the standard of care Mediterranean diet. These changes include established markers of hyperglycemia as well as novel features that can now be investigated as potential therapeutic targets. Our results indicate the microbiome mediates the effect of diet on glycemic, metabolic and immune measurements, with gut microbiome compositional change explaining 12.25% of serum metabolites variance. Although the gut microbiome displays greater compositional changes compared to the oral microbiome, the oral microbiome demonstrates more changes at the genetic level, with trends dependent on environmental richness and species prevalence in the population. In conclusion, our study shows dietary interventions can affect the microbiome, cardiometabolic profile and immune response of the host, and that these factors are well associated with each other, and can be harnessed for new therapeutic modalities.
Introduction
Pre-diabetes affects approximately 7.5% of the global population, serving as a critical precursor to Type 2 diabetes and cardiovascular disease. While dietary intervention is the primary strategy for management, standard "one-size-fits-all" recommendations often yield inconsistent results due to high inter-individual variability in glycemic responses. This study investigates the complex interplay between two dietary strategies—a standard Mediterranean (MED) diet and a Personalized Postprandial glucose-targeting (PPT) diet—and their impact on the gut and oral microbiomes, serum metabolites, and systemic inflammation.
Methods and Study Design
The study was a six-month randomized controlled trial (NCT03222791) involving 200 pre-diabetic participants. The PPT diet utilized a machine-learning algorithm to predict individual blood sugar responses based on microbiome features and clinical data, while the MED diet followed standard guidelines emphasizing whole grains and healthy fats.
A high-resolution multi-omics approach was employed to capture the body's response:
- Metagenomic Sequencing: Analyzed gut (stool) and oral (plaque) microbiomes for species composition and functional pathways.
- Untargeted LC-MS: Measured 1,095 serum metabolites.
- Olink Proteomics: Quantified 76 cytokines.
- Mediation Analysis: Statistical modeling to determine the causal role of the microbiome in metabolic shifts.
Results
The Microbiome as a Mediator of Metabolic Health
A central finding was that the microbiome acts as a critical mediator between diet and host health. Mediation analysis identified specific microbes, such as Faecalibacterium prausnitzii, as bridges translating dietary intake (e.g., fiber or protein) into improved glycemic control and reduced inflammation.
Molecular Shifts and Personalization
Out of 2,803 features measured, 166 showed significant changes. The PPT diet induced more extensive molecular shifts than the MED diet, influencing 19 gut species and 86 metabolites (compared to 5 species and 27 metabolites for MED). Notably, the PPT diet specifically increased nine butyrate-containing compounds known to improve glucose homeostasis. Changes in gut microbiome composition alone explained 12.25% of the variance in serum metabolites.
Gut vs. Oral Dynamics
The study revealed distinct dynamics between microbial environments. The gut microbiome changed primarily in composition (species presence), whereas the oral microbiome remained stable in composition but was highly dynamic at the genetic level, showing significant strain-level flux (p < 10⁻²³).
Discussion
The results demonstrate that personalized dietary interventions can significantly alter the microbiome and cardiometabolic profile of pre-diabetic individuals. The identification of "unclassified" species and "uncharacterized" biochemicals among the most responsive features highlights a vast frontier for novel therapeutic targets. While limited by cytokine sample size, the study provides a robust framework for understanding how the microbiome mediates dietary effects. Future work should explore the long-term sustainability of these shifts and the potential for therapeutic "re-engineering" of the oral microbiome.
Summary updated